S. Kubicka

675 total citations
9 papers, 481 citations indexed

About

S. Kubicka is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Kubicka has authored 9 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Surgery and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Kubicka's work include Colorectal Cancer Treatments and Studies (5 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers) and Cancer Treatment and Pharmacology (3 papers). S. Kubicka is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers) and Cancer Treatment and Pharmacology (3 papers). S. Kubicka collaborates with scholars based in Germany, United States and Japan. S. Kubicka's co-authors include K. Lenhard Rudolph, M.P. Manns, Mario Lorenz, Maja Katrin Tietze, Ullrich Graeven, Wolff Schmiegel, Hans‐Joachim Schmoll, Werner Freier, Axel Grothey and Thomas Seufferlein and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Colorectal Cancer and Metabolic Brain Disease.

In The Last Decade

S. Kubicka

9 papers receiving 467 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Kubicka Germany 8 302 174 167 151 62 9 481
Javier Fernández‐Seara Spain 11 196 0.6× 148 0.9× 258 1.5× 150 1.0× 54 0.9× 14 447
Charles E. Woodall United States 14 236 0.8× 211 1.2× 327 2.0× 274 1.8× 23 0.4× 27 633
Andreas Karachristos United States 12 255 0.8× 203 1.2× 378 2.3× 82 0.5× 44 0.7× 34 537
Declan F.J. Dunne United Kingdom 13 350 1.2× 239 1.4× 427 2.6× 240 1.6× 28 0.5× 20 729
Emrullah Birgin Germany 15 253 0.8× 201 1.2× 280 1.7× 163 1.1× 20 0.3× 59 531
Jaroslav P. Stulc United States 9 438 1.5× 186 1.1× 222 1.3× 39 0.3× 122 2.0× 14 612
E. C. Foerster Germany 14 134 0.4× 243 1.4× 291 1.7× 39 0.3× 34 0.5× 37 483
Alessandro Giani Italy 14 230 0.8× 154 0.9× 221 1.3× 129 0.9× 11 0.2× 44 442
Daniel Ouyang United States 8 135 0.4× 105 0.6× 57 0.3× 118 0.8× 54 0.9× 12 421
Masami Yamauchi Japan 12 131 0.4× 99 0.6× 102 0.6× 187 1.2× 59 1.0× 53 402

Countries citing papers authored by S. Kubicka

Since Specialization
Citations

This map shows the geographic impact of S. Kubicka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Kubicka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Kubicka more than expected).

Fields of papers citing papers by S. Kubicka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Kubicka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Kubicka. The network helps show where S. Kubicka may publish in the future.

Co-authorship network of co-authors of S. Kubicka

This figure shows the co-authorship network connecting the top 25 collaborators of S. Kubicka. A scholar is included among the top collaborators of S. Kubicka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Kubicka. S. Kubicka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Müller‐Deile, Janina, Verena Bröcker, Viktor Grünwald, et al.. (2009). Renal side effects of VEGF-blocking therapy. Clinical Kidney Journal. 3(2). 172–175. 16 indexed citations
2.
Moehler, Markus, Tanja Trarbach, T Seufferlein, et al.. (2008). Cetuximab with irinotecan/NA-FA/5-FU as first-line treatment in advanced gastric cancer: Preliminary results of a non-randomised multi-centre AIO phase II study. mediaTUM (Technical University of Munich). 8 indexed citations
3.
Arkenau, Hendrik‐Tobias, Ullrich Graeven, S. Kubicka, et al.. (2008). Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 7(1). 60–64. 27 indexed citations
4.
Porschen, Rainer, Hendrik‐Tobias Arkenau, S. Kubicka, et al.. (2007). Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group. Journal of Clinical Oncology. 25(27). 4217–4223. 216 indexed citations
5.
Kubicka, S.. (2004). Cholangiozelluläres Karzinom und Gallenblasenkarzinom. Zeitschrift für Gastroenterologie. 42(5). 397–402. 8 indexed citations
6.
Arkenau, Hendrik‐Tobias, Hans‐Joachim Schmoll, S. Kubicka, et al.. (2004). Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis. Journal of Clinical Oncology. 22(14_suppl). 3546–3546. 1 indexed citations
7.
8.
Kubicka, S., K. Lenhard Rudolph, Maja Katrin Tietze, Mario Lorenz, & M.P. Manns. (2002). Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.. PubMed. 48(39). 783–9. 117 indexed citations
9.
Weißenborn, Karin, Ch. Ehrenheim, A. Hori, S. Kubicka, & Michael P. Manns. (1995). Pallidal lesions in patients with liver cirrhosis: clinical and MRI evaluation. Metabolic Brain Disease. 10(3). 219–231. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Javier Fernández‐Seara Breakdown of academic impact, for papers by Charles E. Woodall Breakdown of academic impact, for papers by Andreas Karachristos Breakdown of academic impact, for papers by Declan F.J. Dunne Breakdown of academic impact, for papers by Emrullah Birgin Breakdown of academic impact, for papers by Jaroslav P. Stulc Breakdown of academic impact, for papers by E. C. Foerster Breakdown of academic impact, for papers by Alessandro Giani Breakdown of academic impact, for papers by Daniel Ouyang Breakdown of academic impact, for papers by Masami Yamauchi
Rankless by CCL
2026